

## Appendix 1A

### Application for Admission to the ASX Official List (ASX Listing)

Name of entity<sup>1</sup>

Saluda Medical, Inc.

ABN/ARBN

691 140 360

Date of this form

7 November 2025

We (the entity named above) apply for admission to the <sup>+</sup>official list of ASX Limited (ASX) as an ASX Listing and for <sup>+</sup>quotation of the following <sup>+</sup>securities (or such other number of <sup>+</sup>securities as we may notify to ASX prior to the commencement of <sup>+</sup>quotation):

	<i>Number</i>	<i><sup>+</sup>Class (quoted only)</i>
Estimated maximum number and <sup>+</sup> class of <sup>+</sup> securities to be quoted on ASX at the commencement of quotation on ASX	252,023,810	CHESS Depositary Interests

By giving this form to ASX, we agree to the matters set out in Appendix 1A of the ASX Listing Rules.

Notes:

1. If the entity seeking admission is a trust, the application should be in the form "[Name of responsible entity of trust] in its capacity as responsible entity of [Name of trust]".
2. An entity seeking admission to the official list as an ASX Listing must also provide to ASX the information and documents referred to in the Information Form and Checklist (ASX Listing) published on the ASX website.

# Information Form and Checklist

## (ASX Listing)

Name of entity

Saluda Medical, Inc.

**We (the entity named above) supply the following information and documents to support our application for admission to the official list of ASX Limited (ASX) as an ASX Listing.**

**Note:** by giving an Appendix 1A *Application for Admission to the ASX Official List (ASX Listing)* to ASX, the entity is taken to have warranted that all of the information and documents it has given, or will give, to ASX in connection with its admission to the official list and the quotation of its securities are, or will be, accurate, complete and not misleading. It also indemnifies ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from, or connected with, any breach of that warranty (see Appendix 1A of the ASX Listing Rules).

The information and documents referred to in this Information Form and Checklist (including any annexures to it) are covered by the warranty and indemnity mentioned above.

Terms used in this Information Form and Checklist and in any Annexures have the same meaning as in the ASX Listing Rules.

If an applicant is admitted to the Official List of ASX, this Information Form and Checklist will be released on the Market Announcements Platform at the time of admission. Prior to admission, and promptly after this Information Form and Checklist is submitted to ASX, certain key details regarding the upcoming listing will be published on the ASX website at: <https://www2.asx.com.au/listings/upcoming-floats-and-listings>.

## Part 1 – Key Information

**Instructions:** please complete each applicable item below. If an item is not applicable, please mark it as “N/A”.

### Corporate details<sup>1</sup>

Legal name <sup>2</sup>	Saluda Medical, Inc.	
Trading name	Saluda Medical, Inc.	
Date of incorporation or establishment	7 February 2023	
Place of incorporation or establishment	Country	United States
	State (Province, County, etc.)	Delaware
All Australian registration numbers (as appropriate)	ABN	N/A
	ACN	N/A
	ARSN	N/A
	ARBN	691 140 360
Foreign incorporation reference number, <sup>3</sup> if applicable	Delaware file number 7079315	

<sup>1</sup> If the entity applying for admission to the official list is a stapled group, please provide these details for each entity comprising the stapled group.

<sup>2</sup> As registered with ASIC. If it is a foreign entity, reflect the entity legal name as registered in the country of incorporation or establishment, if applicable.

<sup>3</sup> The equivalent registration number to an ABN or ACN in the country of incorporation or establishment, where the country of incorporation or establishment is not Australia.

Legal entity identifier (LEI), <sup>4</sup> if applicable	N/A
Legislation under which incorporated or established	Delaware General Corporation Law
Address of registered office in place of incorporation or establishment	251 Little Falls Drive, Wilmington DE 19808, County of New Castle, United States
Main business activity	The entity is a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel neuromodulation platform.
Country where main business activity is mostly carried on	United States
Other exchanges on which the entity is listed	N/A
Street address of principal administrative office	9401 James Ave. S, Suite 132, Bloomington MN, United States
Postal address of principal administrative office	9401 James Ave. S, Suite 132, Bloomington MN, United States
Telephone number of principal administrative office	+1 (952) 491-4241
Email address for investor enquiries	<a href="mailto:Investors@saludamedical.com">Investors@saludamedical.com</a>
Website URL	<a href="https://www.saludamedical.com">https://www.saludamedical.com</a>

#### Board and senior management details<sup>5</sup>

Full name and title of chairperson of directors	Douglas Evan Godshall, Chairman
Full names of all existing directors	<p>Barry John Regan, President and CEO</p> <p>Douglas Evan Godshall, Chairman and non-executive director</p> <p>Geoffrey Edward Duncan Brooke, non-executive director</p> <p>Robert Carrington Faulkner, non-executive director</p> <p>Catherine Brighid Livingstone, non-executive director</p> <p>Robert Jon Palmisano, non-executive director</p> <p>Quentin Blackford, non-executive director</p>

<sup>4</sup> The LEI is a standard identifier that provides verified data on legal entities registered on a centralised system, the Global LEI System. Providing a LEI is voluntary. If the entity does not have a LEI leave this field blank. For Issuers who choose to voluntarily provide their LEI (where available), ASX will record and link the LEI of the issuer to each International Securities Identification Number (ISIN) allocated to financial instruments issued by that issuer and quoted on ASX. ASX will also provide the ISIN-LEI mapping to the Association of National Numbering Agencies (ANNA) Service Bureau (ASB) for the purpose of the ISIN-LEI mapping initiative, and this information will then be made publicly available on both the ANNA and Global Legal Entity Identifier Foundation (GLEIF) websites. Once publically available, any person may use the LEI information (including the ISIN-LEI mapping data) for any purpose without restriction.

<sup>5</sup> If the entity applying for admission to the official list is a trust, enter the board and senior management details for the responsible entity of the trust.

Full names of any persons proposed to be appointed as additional or replacement directors	N/A
Full name and title of CEO/managing director	Barry John Regan, President and Chief Executive Officer
Email address of CEO/managing director	<a href="mailto:Barry.Regan@saludamedical.com">Barry.Regan@saludamedical.com</a>
Full name and title of CFO	James Erickson, Chief Financial Officer
Email address of CFO	<a href="mailto:Jim.Erickson@saludamedical.com">Jim.Erickson@saludamedical.com</a>
Full name and title of company secretary	Kristin Caplice, Company Secretary
Email address of company secretary	<a href="mailto:Kristin.Caplice@saludamedical.com">Kristin.Caplice@saludamedical.com</a>

### Third party company secretarial service provider details (if applicable)<sup>6</sup>

Service provider entity name <sup>7</sup>	N/A	
All Australian registration numbers (as appropriate)	ABN	N/A
	ACN	N/A
	ARBN	N/A
Foreign incorporation reference number, <sup>8</sup> if applicable	N/A	
Place of incorporation or establishment	Country	N/A
	State (Province, County, etc.)	N/A
Address	N/A	

### ASX compliance contact details<sup>9</sup>

Full name and title of ASX contact(s)	Cameron Billingsley
Business address of ASX contact(s)	PFM Legal Pty Ltd, 8 Brown Street, Bronte, NSW 2000
Business phone number of ASX contact(s)	+61 2 8760 1480
Mobile phone number of ASX contact(s)	0410626421

<sup>6</sup> Please provide these details if the entity seeking admission has engaged an external entity to provide company secretarial services to it.

<sup>7</sup> As registered with ASIC. If it is a foreign entity, reflect the entity legal name as registered in the country of incorporation or establishment, if applicable.

<sup>8</sup> The equivalent registration number to an ABN or ACN in the country of incorporation or establishment, where the country of incorporation or establishment is not Australia.

<sup>9</sup> Under Listing Rule 1.1 Condition 13, a listed entity must appoint a person responsible for communication with ASX on Listing Rule matters. You can appoint more than one person to cater for situations where the primary nominated contact is not available.

Email address of ASX contact(s)	Cameron@PFMPL.com.au
---------------------------------	----------------------

### Investor relations contact details

Full name and title of person responsible for investor relations	N/A at present
Business phone number of person responsible for investor relations	N/A at present
Email address of person responsible for investor relations	N/A at present

### Auditor details<sup>10</sup>

Full name of auditor	Grant Thornton LLP
----------------------	--------------------

### Registry details<sup>11</sup>

Name of securities registry	CDI Registry: Computershare Investor Services Pty Limited Share Registry: Computershare Trust Company, N.A.
Address of securities registry	Computershare Investor Services Pty Limited GPO Box 2975 Melbourne, Victoria 3001 Australia
Phone number of securities registry	Computershare Investor Services Pty Limited: 1300 850 505 (within Australia) or +61 3 9415 4000 (outside Australia)
Fax number of securities registry	+61 03 9473 2366
Email address of securities registry	N/A
Type of sub-registers the entity will operate <sup>12</sup>	CHESS and issuer sponsored sub registers (CDIs) and an uncertificated principal register

### Key dates

Annual financial year end date	30 June
Month in which annual meeting is usually held (or intended to be held) <sup>13</sup>	November

<sup>10</sup> In certain cases, ASX may require the applicant to provide information about the qualifications and experience of its auditor for release to the market before quotation commences (see Guidance Note 1 section 2.12).

<sup>11</sup> If the entity has different registries for different classes of securities, please indicate clearly which registry details apply to which class of securities.

<sup>12</sup> Example: CHESS and issuer sponsored sub-registers (see Guidance Note 1 section 3.23).

<sup>13</sup> May not apply to some trusts.

Months in which dividends or distributions are usually paid (or are intended to be paid), if applicable	N/A
---	-----

### Trusts – additional details

Name of responsible entity	N/A	
All Australian registration numbers (as appropriate)	ABN	N/A
	ACN	N/A
Place of incorporation or establishment	Country	N/A
	State (Province, County, etc.)	N/A
Legal Entity Identifier (LEI), if applicable <sup>14</sup>	N/A	
Address	N/A	
Full names of the members of the compliance committee (if any)	N/A	

### Entities incorporated or established outside Australia – additional details

Name <sup>15</sup> of the entity's Australian agent for service of process	Saluda Medical Pty Limited	
All Australian registration numbers of entity's Australian agent for service of process (as appropriate)	ABN	14 145 902 272
	ACN	145 902 272
Place of incorporation or establishment of the entity's Australian agent for service of process	Country	Australia
	State (Province, County, etc.)	New South Wales
Address of the entity's Australian agent for service of process	Level 2, 5 Eden Park Drive, Macquarie Park NSW 2113	
If the entity has or intends to have a certificated sub-register for quoted securities, the location of the Australian sub-register	Computershare Investor Services Pty Limited GPO Box 2975 Melbourne VIC 3001 Australia  Telephone: 1300 850 505 (within Australia) or +61 3 9415 5000 (outside Australia)  www.computershare.com	
Address of registered office in Australia (if any)	Level 2, 5 Eden Park Drive, Macquarie Park NSW 2113	

<sup>14</sup> Refer to footnote 5 above for further details regarding LEIs.

<sup>15</sup> As registered with ASIC.

**Entities listed or to be listed on another exchange or exchanges**

Name of the other exchange(s) where the entity is or proposes to be listed	N/A
Is the ASX listing intended to be the entity's primary or secondary listing?	Primary

## Part 2 – Checklist Confirming Compliance with Admission Requirements

**Instructions:** please indicate in the “Location/Confirmation” column for each item below and in any Annexures where the information or document referred to in that item is to be found (e.g. in the case of information, the specific page reference in the Offer Document where that information is located or, in the case of a document, the folder tab number where that document is located). If the item asks for confirmation of a matter, you may simply enter “Confirmed” in the “Location/Confirmation” column. If an item is not applicable, please mark it as “N/A”.

In this regard, it will greatly assist ASX and speed up its review of the application if the various documents referred to in this Checklist and any Annexures are provided both in hard copy and in electronic form in one or more folders and/or in any other appropriate electronic form containing consecutively numbered and titled documents (e.g. ‘Attachment 1 – Certificate of Incorporation’, ‘Attachment 2 – Constitution’, etc.), together with a document index. Where this Checklist indicates that an original document is required, ASX will also accept a certified copy of the relevant document.

Note that completion of this Checklist and any Annexures is not to be taken to represent that the entity is necessarily in full or substantial compliance with the ASX Listing Rules or that ASX will admit the entity to its official list. Admission to the official list is in ASX’s absolute discretion and ASX may refuse admission without giving any reasons (see Listing Rule 1.19).

A reference in this Checklist and in any Annexures to the “Offer Document” means the listing prospectus, product disclosure statement or information memorandum lodged by the applicant with ASX pursuant to Listing Rule 1.1 Condition 3.

If the applicant lodges a supplementary or replacement prospectus, product disclosure statement or information memorandum with ASX, ASX may require it to update this Checklist and any Annexures by reference to that document.

### Key supporting documents

No	Item	Location/Confirmation
1.	Entity’s certificate of incorporation, certificate of registration or other evidence of status (including any change of name)	<b>Tab 1 – Amended and Restated Certificate of Incorporation</b>
2.	Entity’s constitution (Listing Rule 1.1 Condition 2)	<b>Tab 3 – Amended and Restated Bylaws</b>
3.	Either: (a) confirmation that the entity’s constitution includes the provisions of Appendix 15A or Appendix 15B (as applicable); or (b) a completed checklist that the constitution complies with the Listing Rules (Listing Rule 1.1 Condition 2) <sup>16</sup>	The entity’s Amended and Restated bylaws includes the provisions of Appendix 15A. Refer article 12 – ASX Listing
4.	Offer Document, as lodged with ASIC (Listing Rule 1.1 Condition 3)	<b>Tab 4 – Prospectus</b>
5.	Where in the Offer Document is the prominent statement that ASX takes no responsibility for the contents of the Offer Document (Listing Rule 1.1 Condition 3)?	Important Information and Section 8.12 of the Prospectus – Trading on the ASX
6.	Has (or have) the ASX contact(s) completed an approved listing rule compliance course and attained a satisfactory pass mark in the examination for that course? <sup>17</sup>	Yes
7.	Executed ASX Online agreement confirming that documents may be given to ASX and authenticated electronically (Listing Rule 1.1 Condition 14) <sup>18</sup>	<b>Tab 5 – ASX Online Agreement</b>
8.	If the entity’s corporate governance statement <sup>19</sup> is included in its Offer Document, the page reference where it is included. Otherwise, a copy of the entity’s corporate governance statement (Listing Rule 1.1 Condition 16)	<b>Tab 6 – Corporate Governance Statement</b>

<sup>16</sup> An electronic copy of the checklist is available from the ASX Compliance Downloads page on ASX’s website.

<sup>17</sup> If the answer is “no”, each ASX contact must complete the course and attain a satisfactory pass mark in the examination for the course prior to the entity’s admission to the official list.

<sup>18</sup> An electronic copy of the ASX Online Agreement is available from the ASX Compliance Downloads page on ASX’s website.

<sup>19</sup> The entity’s “corporate governance statement” is the statement disclosing the extent to which the entity will follow, as at the date of its admission to the official list, the recommendations set by the ASX Corporate Governance Council. If the entity does not intend to follow all the recommendations on its admission to the official list, the entity must separately identify each recommendation that will not be followed and state its reasons for not following the recommendation and what (if any) alternative governance practices it intends to adopt in lieu of the recommendation.



Nº	Item	Location/Confirmation
9.	If the entity will be included in the S & P All Ordinaries Index on admission to the official list, <sup>20</sup> where in its Offer Document does it state that it will have an audit committee (Listing Rule 1.1 Condition 17)?	N/A  The Audit and Risk Committee is described at Section 7.8.2 of the Prospectus – Board committees
10.	If the entity will be included in the S & P / ASX 300 Index on admission to the official list, <sup>21</sup> where in its Offer Document does it state that it will comply with the recommendations set by the ASX Corporate Governance Council in relation to the composition and operation of the audit committee (Listing Rule 1.1 Condition 17)?	N/A  The composition and operation of Audit and Risk Committee is described at Section 7.8.2 of the Prospectus – Board committees
11.	If the entity will be included in the S & P / ASX 300 Index on admission to the official list, <sup>22</sup> where in its Offer Document does it state that it will have a remuneration committee comprised solely of non-executive directors (Listing Rule 1.1 Condition 18)	N/A  The composition of the Compensation Committee is described at Section 7.8.2 of the Prospectus – Board committees
12.	If the entity's trading policy is included in its Offer Document, the page reference where it is included. Otherwise, a copy of the entity's trading policy (Listing Rule 1.1 Condition 19)	<b>Tab 7 –Insider Trading Compliance Policy</b>
13.	For each director or proposed director, the CEO or proposed CEO, and the CFO or proposed CFO (together, "relevant officers") of the entity at the date of listing, <sup>23</sup> a list of the countries in which they have resided over the past 10 years (Listing Rule 1.1 Condition 20 and Guidance Note 1 section 3.21) <sup>24</sup>	Douglas Evan Godshall, Chair and non-executive director <ul style="list-style-type: none"> <li>United States</li> </ul> Geoffrey Edward Duncan Brooke, non-executive director <ul style="list-style-type: none"> <li>Australia</li> </ul> Robert Carrington Faulkner, non-executive director <ul style="list-style-type: none"> <li>United States</li> </ul> Catherine Brighid Livingstone, non-executive director <ul style="list-style-type: none"> <li>Australia</li> </ul> Robert Jon Palmisano, non-executive director <ul style="list-style-type: none"> <li>United States</li> </ul> Quentin Blackford, non-executive director <ul style="list-style-type: none"> <li>United States</li> </ul> Barry John Regan, President and CEO <ul style="list-style-type: none"> <li>United States</li> </ul> James Alan Erickson, CFO <ul style="list-style-type: none"> <li>United States</li> </ul>
14.	For each relevant officer, a list of any other names or alias they have used in the past 10 years, including any maiden name or married name <sup>25</sup> (Listing Rule 1.1 Condition 20 and Guidance Note 1 section 3.21)	<ul style="list-style-type: none"> <li>N/A</li> </ul>

<sup>20</sup> If the entity is unsure whether they will be included in the S & P All Ordinaries Index on admission to the official list, they should contact ASX or S & P.

<sup>21</sup> If the entity is unsure whether they will be included in the S & P / ASX 300 Index on admission to the official list, they should contact ASX or S & P.

<sup>22</sup> If the entity is unsure whether they will be included in the S & P / ASX 300 Index on admission to the official list, they should contact ASX or S & P.

<sup>23</sup> If the entity applying for admission to the official list is a trust, references in items 13, 14, 15, 16, 17, 18 and 19 to a relevant officer mean a relevant officer of the responsible entity of the trust.

<sup>24</sup> The information referred to in items 13, 14, 15, 16, 17, 18 and 19 is required so that ASX can be satisfied that the relevant officer is of good fame and character under Listing Rule 1 Condition 20.

<sup>25</sup> The sample statutory declaration referred to in item 19 below addresses this requirement. Note that if the relevant officer has used another name or alias (including a maiden name or married name) in the past 10 years, the criminal record and bankruptcy checks referred to in items 15, 16, 17, 18 must cover all of the names or aliases the relevant officer has used over that period.

Nº	Item	Location/Confirmation
15.	For each relevant officer who is or has in the past 10 years been a resident of Australia, an original or certified true copy of a national criminal history check obtained from the Australian Federal Police, a State or Territory police service or a broker accredited by Australian Criminal Intelligence Commission which is not more than 12 months old (Listing Rule 1.1 Condition 20 and Guidance Note 1 section 3.21)	<b>Tab 8 – Background Checks</b> <ul style="list-style-type: none"> <li>• Catherine Brighid Livingstone</li> <li>• Geoffrey Edward Duncan Brooke</li> </ul>
16.	For each relevant officer who is or has in the past 10 years been a resident of a country other than Australia, an original or certified true copy of an equivalent national criminal history check to that mentioned in item 15 above for each country in which the relevant officer has resided over the past 10 years (in English or together with a certified English translation) which is not more than 12 months old or, if such a check is not available in any such country, a statutory declaration <sup>26</sup> from the relevant officer confirming that fact and that he or she has not been convicted in that country of: <ul style="list-style-type: none"> <li>(a) any criminal offence involving fraud, dishonesty, misrepresentation, concealment of material facts or breach of his or her duties as a director or officer of a company or other entity; or</li> <li>(b) any other criminal offence which at the time carried a maximum term of imprisonment of five years or more (regardless of the period, if any, for which he or she was sentenced),</li> </ul> or, if that is not the case, a statement to that effect and a detailed explanation of the circumstances involved (Listing Rule 1.1 Condition 20 and Guidance Note 1 section 3.21)	<b>Tab 9 – Background Checks</b> <ul style="list-style-type: none"> <li>• Barry John Regan</li> <li>• James Alan Erickson</li> <li>• Douglas Evan Godshall</li> <li>• Robert Carrington Faulkner</li> <li>• Robert Jon Palmisano</li> <li>• Quentin Blackford</li> </ul>
17.	For each relevant officer who is or has in the past 10 years been a resident of Australia, an original or certified true copy of a search of the Australian Financial Security Authority National Personal Insolvency Index which is not more than 12 months old (Listing Rule 1.1 Condition 20 and Guidance Note 1 section 3.21)	<b>Tab 8 – Background Checks</b> <ul style="list-style-type: none"> <li>• Catherine Brighid Livingstone</li> <li>• Geoffrey Edward Duncan Brooke</li> </ul>
18.	For each relevant officer who is or has in the past 10 years been a resident of a country other than Australia, an original or certified true copy of an equivalent national bankruptcy check to that mentioned in item 17 above for each country in which the relevant officer has resided over the past 10 years (in English or together with a certified English translation) which is not more than 12 months old or if such a check is not available in any such country, a statutory declaration <sup>27</sup> from the relevant officer confirming that fact and that he or she has not been declared a bankrupt or been an insolvent under administration in that country or, if that is not the case, a statement to that effect and a detailed explanation of the circumstances involved (Listing Rule 1.1 Condition 20 and Guidance Note 1 section 3.21)	<b>Tab 9 – Background Checks</b> <ul style="list-style-type: none"> <li>• Barry John Regan</li> <li>• James Alan Erickson</li> <li>• Douglas Evan Godshall</li> <li>• Robert Carrington Faulkner</li> <li>• Robert Jon Palmisano</li> <li>• Quentin Steven Blackford</li> </ul>
19.	A statutory declaration <sup>28</sup> from each relevant officer specifying whether they have used any other name or alias in the past 10 years and confirming that: <ul style="list-style-type: none"> <li>(a) the relevant officer has not been the subject of any criminal or civil penalty proceedings or other enforcement action by any government agency in which he or she was found to have engaged in behaviour involving fraud, dishonesty, misrepresentation, concealment of material facts or breach of duty;</li> <li>(b) the relevant officer has not been refused membership of, or had their membership suspended or cancelled by, any professional body on the ground that he or she has engaged in behaviour involving fraud, dishonesty, misrepresentation, concealment of material facts or breach of duty;</li> <li>(c) the relevant officer has not been the subject of any disciplinary action (including any censure, monetary penalty or banning order) by a securities</li> </ul>	<b>Tab 10 – Statutory Declarations</b> <ul style="list-style-type: none"> <li>• Barry John Regan</li> <li>• James Alan Erickson</li> <li>• Douglas Evan Godshall</li> <li>• Geoffrey Edward Duncan Brooke</li> <li>• Robert Carrington Faulkner</li> <li>• Catherine Brighid Livingstone</li> <li>• Robert Jon Palmisano</li> <li>• Quentin Steven Blackford</li> </ul>

<sup>26</sup> The sample statutory declaration referred to in item 19 below also addresses this requirement.

<sup>27</sup> The sample statutory declaration referred to in item 19 below also addresses this requirement.

<sup>28</sup> A sample statutory declaration is available from the ASX Compliance Downloads page on ASX's website.

Nº	Item	Location/Confirmation
	<p>exchange or other authority responsible for regulating securities markets for failure to comply with his or her obligations as a director or officer of a listed entity;</p> <p>(d) no listed entity of which he or she was a relevant officer (or, in the case of a listed trust, in respect of which he or she was a relevant officer of the responsible entity of the trust) at the time of the relevant conduct has been the subject of any disciplinary action (including any censure, monetary penalty, suspension of trading or termination of listing) by a securities exchange or other authority responsible for regulating securities markets for failure to comply with its obligations under the Listing Rules applicable to that entity; and</p> <p>(e) the relevant officer is not aware of any pending or threatened investigation or enquiry by a government agency, professional body, securities exchange or other authority responsible for regulating securities markets that could lead to proceedings or action of the type described in (a), (b), (c) or (d) above,</p> <p>or, if the relevant officer is not able to give such confirmation, a statement to that effect and a detailed explanation of the circumstances involved (Listing Rule 1.1 Condition 20 and Guidance Note 1 section 3.21)</p>	
20.	A specimen certificate/holding statement for each class of securities to be quoted or a specimen holding statement for CDIs (as applicable)	<b>Tab 11 – Specimen holding statement for CDIs</b>
21.	<p>Please either:</p> <p>(a) enter “Confirmed” in the column to the right to confirm that the entity has not previously applied for, and been refused or withdrawn its application for, admission to the official list of another securities exchange, or</p> <p>(b) attach a statement explaining the circumstances and state the location of that statement</p>	Confirmed.
22.	Please enter “Confirmed” in the column to the right to confirm that the entity has paid its initial listing fee <sup>29</sup>	Confirmed

## Group structure

23.	Where in the Offer Document is there a diagram showing the group structure of the entity, identifying (where applicable) each material child entity and the nature and location of the business activities it undertakes	Section 12.2 – Corporate Structure
24.	If the entity has any material child entities, where in the Offer Document is there a list of all such child entities stating, in each case, its name, where it is incorporated or established, the nature of its business and the entity's percentage holding in it?	Section 12.2 – Corporate Structure
25.	If the entity has any material investments in associated entities for which it will apply equity accounting, where in the Offer Document is there a list of all such associated entities stating, in each case, its name, where it is incorporated or established, the nature of its business and the entity's percentage holding in it?	N/A

<sup>29</sup> See Guidance Notes 15 and 15A for the fees payable on the application. You can also use the ASX online equity listing fees calculator: <http://www.asx.com.au/prices/cost-listing.htm>. Payment should be made either by cheque made payable to ASX Operations Pty Ltd or by electronic funds transfer to the following account:

Bank: National Australia Bank  
Account Name: ASX Operations Pty Ltd  
BSB: 082 057  
A/C: 494728375  
Swift Code (Overseas Customers): NATAAU3202S

If payment is made by electronic funds transfer, please email your remittance advice to [ar@asx.com.au](mailto:ar@asx.com.au), describing the payment as the “initial listing fee” and including the name of the entity applying for admission, the ASX home branch where the entity has lodged its application (ie Sydney, Melbourne or Perth) and the amount paid.

Nº	Item	Location/Confirmation
26.	If the entity has a material interest in a joint venture, where in the Offer Document is there a description of the joint venture agreement, including the parties to the agreement and their respective rights and obligations under the agreement?	N/A
27.	If the entity does not hold its material assets and business operations directly itself or indirectly through a child entity, where in the Offer Document is there an explanation of why that structure has been employed and the risks associated with it?	N/A

## Capital structure

28.	Where in the Offer Document is there a table showing the existing and proposed capital structure of the entity, broken down as follows: (a) the number and class of each equity security and each debt security currently on issue; and (b) the number and class of each equity security and each debt security proposed to be issued between the date of this application and the date the entity is admitted to the official list; and (c) the resulting total number of each class of equity security and debt security proposed to be on issue at the date the entity is admitted to the official list; and (d) the number and class of each equity security proposed to be issued following admission in accordance with material contracts or agreements?  Note: This applies whether the securities are to be quoted on ASX or not. If the entity is proposing to issue a minimum, maximum or oversubscription number of securities, the table should be presented to disclose each scenario.	Section 8.5.1 – Capital Structure
29.	If any class of securities referred to in the table mentioned in item 28 are not ordinary securities, where in the Offer Document does it disclose the terms applicable to those securities?  Note: This applies whether the securities are to be quoted on ASX or not. For equity securities (other than options to acquire unissued securities or convertible debt securities), this should state whether they are fully paid or partly paid; if they are partly paid, the amount paid up and the amount owing per security; voting rights; rights to dividends or distributions; and conversion terms (if applicable). For options to acquire unissued securities, this should state the number outstanding, exercise prices; exercise terms and expiry dates. For debt securities or convertible debt securities, this should state their nominal or face value; rate of interest; dates of payment of interest; date and terms of repayment or redemption; and conversion terms (if applicable).	Section 12.4 – Options Section 12.5 – RSUs Section 12.6 – Warrants
30.	Where in the Offer Document does it confirm that the entity's free float at the time of listing will be not less than 20% (Listing Rule 1.1 Condition 7)?	Section 8.5.1 – Capital Structure
31.	Where in the Offer Document does it confirm that the issue/sale price of all securities for which the entity seeks quotation is at least 20 cents in cash (Listing Rule 2.1 Condition 2)?	Section 8.1 – Overview of the Offer Section 8.6 – What is the Offer Price?
32.	If the entity has or proposes to have any options on issue, where in the Offer Document does it confirm that the exercise price for each underlying security is at least 20 cents in cash (Listing Rule 1.1 Condition 12)?	The exercise prices of the options on issue are set out in Section 12.4.
33.	If the entity has any partly paid securities and it is not a no liability company, where in the Offer Document does it disclose the entity's call program, including the date and amount of each proposed call and whether it allows for any extension for payment of a call (Listing Rule 2.1 Condition 4)?	N/A
34.	Is the entity proposing to offer any securities by way of a bookbuild? If so, please enter "Confirmed" in the column to the right to indicate that the entity	N/A

Nº	Item	Location/Confirmation
	is aware of the disclosure requirements for bookbuilds in Annexure A to Guidance Note 1 and has made appropriate arrangements with the bookrunner to obtain this information.	

## Business information

35. Where in the Offer Document is there a description of the history of the entity?	Section 3.2 – Company History
36. Where in the Offer Document is there a description of the entity's existing and proposed activities and level of operations?	Section 3 – Company Overview, including Section 3.6 – Saluda's product pipeline, Section 3.7 – Saluda's clinical results and studies and Section 3.13 – 'Saluda's growth strategies
37. Where in the Offer Document is there a description of the material business risks the entity faces?	Section 4 – Risks
38. Where in the Offer Document is there a table setting out the proposed use of the proceeds of the offer?	Section 1.9 – Proposed sources and uses of funds associated with the Offer Section 8.4 – Purpose of the Offer and sources and use of funds

## Related parties, promoters and advisers

39. Has the entity undertaken a placement of securities in the last 2 years in which a related party or their associates, a promoter or their associates, or an adviser involved in the offer or their associates, have participated?	
<p>If so, please attach a statement</p> <p>(a) explaining the circumstances of the placement;</p> <p>(b) listing the names and addresses of the participants in the placement, the number of securities they received in the placement and the consideration they provided for those securities; and</p> <p>(c) identifying the participants in the placement who are a related party or associate of a related party, a promoter or associate of a promoter, or an adviser or an associate of an adviser.</p>	<p>In October 2025, the Company completed a private placement of its common stock in which certain existing Shareholders of the Company purchased shares of common stock at a price per Share of US\$0.330 for the aggregate amount of US\$15,000,000 (<b>Bridge Financing</b>). Immediately prior to the closing of the Bridge Financing, all shares of outstanding preferred stock of the Company and the principal and accrued interest of all outstanding convertible notes of the Company were converted into shares of common stock of the Company (<b>Converted Common Stock</b>). Warrants that were previously exercisable for shares of preferred stock were automatically adjusted to warrants exercisable for shares of common stock at the same rate the shares of preferred stock underlying the warrants were converted into shares of Converted Common Stock, other than the warrant issued pursuant to the Perceptive Term Loan, which was amended and restated to a warrant exercisable for a number of shares of common stock determined</p>

Nº Item

Location/Confirmation

based on reference to the original value of the warrant under the Perceptive Term Loan. As part of the Bridge Financing, certain eligible Shareholders of the Company who invested their pro rata portion of the Bridge Financing at the initial closing exchanged shares of Converted Common Stock for new shares of common stock at rate equal to the original issue price of the Converted Common Stock divided by a price per share equal to US\$0.019.

As part of the Bridge Financing, the investors therein also have the option, if additional funds are requested by the Company, to purchase additional shares of common stock, in the aggregate amount of up to \$35,000,000, which financing would either be completed as an additional closing of the Bridge Financing or as part of the Offer.

Mr Godshall, the Chair of the Company, held a convertible note of the Company prior to the Bridge Financing and that convertible note converted as part of the Bridge Financing into, together with the exchange of Converted Common Stock related to the convertible note in the Bridge Financing, 14,029,145 Shares (or 272,410 Shares assuming the Restructuring has occurred). Mr Godshall also purchased 825,230 Shares (or 16,023 Shares assuming the Restructuring has occurred) in the Bridge Financing.

Ms Caplice, the Chief Legal Officer of the Company, also held a convertible note of the Company prior to the Bridge Financing and that convertible note converted as part of the Bridge Financing into, together with the exchange of Converted Common Stock related to the convertible note in the Bridge Financing, 1,054,365 Shares (or 20,472 Shares assuming the Restructuring has occurred). Ms Caplice also purchased 62,019 Shares (or 1,204 Shares assuming the Restructuring has occurred) in the Bridge Financing.

Nº	Item	Location/Confirmation
40.	Does an adviser to the offer have a material interest in the success of the offer over and above normal professional fees for services rendered in connection with the offer?  If so, where in the Offer Document is there a clear and concise statement explaining in one location all of the interests that adviser has in the success of the offer, including (without limitation): (a) the number and type of securities in the entity in which the adviser and its associates currently have a relevant interest; (b) details of the consideration paid or provided by the adviser or its associates for the securities referred to in (a) above; (c) the fees or other consideration the adviser or an associate may receive for services provided in connection with the offer; (d) the fees or other consideration the adviser or an associate may receive under any ongoing mandate they may have with the entity post the offer; (e) if the consideration in (c) or (d) above includes any convertible securities (including options, performance shares or performance rights), details of the number and terms of those securities, the percentage of the entity's issued capital at listing they will convert into if they are converted, the value the entity believes the convertible securities are worth and the basis on which the entity has determined that value; and (f) if the adviser or any of its associates have participated in a placement of securities by the entity in the preceding 2 years, full details of the securities they received in the placement and the consideration they paid or provided for those securities?	N/A

### Other information and documents

41.	Where in the Offer Document is there a description of the entity's proposed dividend/distribution policy?	Section 12.11 – Dividend policy
42.	Does the entity have or propose to have a dividend or distribution reinvestment plan?  If so, where are the existence and material terms of the plan disclosed in the Offer Document?	N/A
	Terms of the plan	N/A
43.	Does the entity have or propose to have an employee incentive scheme?  If so, where are the existence and material terms of the scheme disclosed in the Offer Document?	Section 7.6 – Incentive Plans
	Where in the Offer Document is there a statement as to whether directors <sup>30</sup> are entitled to participate in the scheme and, if they are, the extent to which they currently participate or are proposed to participate?	Section 7.6.1 – 2023 Incentive Award Plan, Section 7.4.2 – Employment arrangements with President and CEO, Section 7.4.6(b) – Current equity awards
	Terms of the scheme	<b>Tab 12.1</b> – 2023 Incentive Award Plan and 2023 Incentive Award Plan Australian sub-plan <b>Tab 12.2</b> – 2023 Employee Option Plan
44.	Has the entity entered into any material contracts (including any underwriting agreement relating to the securities to be quoted on ASX)?  If so, where are the existence and main terms of those material contracts disclosed in the Offer Document?	Yes. Section 9 – Material Contracts

<sup>30</sup> If the entity applying for admission to the official list is a trust, references to a director mean a director of the responsible entity of the trust.

Nº	Item	Location/Confirmation
	<p>All of the material contracts referred to in the Offer Document which relate to the securities to be quoted on ASX or for which completion is a condition of the Offer</p>	<p><b>Tab 13:</b>  13.1 – Supply agreement dated 21 January 2020 (as amended on 1 March 2022) between (amongst others) Saluda Medical Pty Ltd and Integer Holdings Corporation;  13.2 – Supply and Purchase Agreement dated 1 November 2024 between Saluda Medical Americas, Inc and Heraeus Medical Components LLC, as amended on 14 January 2025.  13.3 – Credit Agreement and Guaranty with Perceptive Credit Holdings IV, LP.  13.4 – Amended and Restated Investor Rights Agreement  13.5 – Underwriting Agreement</p>
45.	<p>If the entity is not an externally managed trust and the following information is included in the Offer Document, the page reference where it is included. Otherwise, either a summary of the material terms of, or a copy of, any employment, service or consultancy agreement the entity or a child entity has entered into with:</p> <p>(a) its CEO or proposed CEO;  (b) any of its directors or proposed directors; or  (c) any other person or entity who is a related party of the persons referred to in (a) or (b) above (Listing Rule 3.16.4)</p> <p>Note: this requirement does not apply to an externally managed trust. If the entity applying for admission to the official list is an internally managed trust, references to a CEO, proposed CEO, director or proposed director mean a CEO, proposed CEO, director or proposed director of the responsible entity of the trust.</p>	<p>Yes. See:</p> <ul style="list-style-type: none"> <li>Section 7.4.2 – Employment arrangements with President and CEO</li> <li>Section 7.4.6 – Non-Executive Directors</li> <li>Section 7.4.8 – Indemnification arrangements with the Directors</li> </ul> <p><b>Tab 14 –</b></p> <ul style="list-style-type: none"> <li>Employment Agreement with Barry John Regan and Amendment to Employment Agreement with Barry John Regan</li> <li>Form of Director Indemnification Agreement</li> </ul>
46.	<p>Please enter “Confirmed” in the column to the right to indicate that the material contracts summarised in the Offer Document include, in addition to those mentioned in item 45, any other material contract(s) the entity or a child entity has entered into with:</p> <p>(a) its CEO or proposed CEO;  (b) any of its directors or proposed directors; or  (c) any other person or entity who is a related party of the persons referred to in (a) or (b) above</p> <p>Note: this requirement does not apply to an externally managed trust. If the entity applying for admission to the official list is an internally managed trust, references to a CEO, proposed CEO, director or proposed director mean a CEO, proposed CEO, director or proposed director of the responsible entity of the trust.</p>	<p>Confirmed.</p>
47.	<p>Please enter “Confirmed” in the column to the right to indicate that all information that a reasonable person would expect to have a material effect on the price or value of the securities to be quoted is included in or provided with this Information Form and Checklist</p>	<p>Confirmed.</p>
48.	<p>Entity’s most recent annual report</p>	<p>N/A</p>



Nº Item	Location/Confirmation
<b>Entities that are trusts</b>	
49. Evidence that the entity is a registered managed investment scheme or has an exemption from ASIC from that requirement (Listing Rule 1.1 Condition 5(a))	N/A
50. If the entity is exempted from the requirement to be a registered managed investment scheme, evidence that its responsible entity is either an Australian company or registered as a foreign company carrying on business in Australia under the Corporations Act (Listing Rule 1.1 Condition 5(b))	N/A
51. Please enter "Confirmed" in the column to the right to indicate that the responsible entity is not under an obligation to allow a security holder to withdraw from the trust (Listing Rule 1.1 Condition 5(c))	N/A

### Entities applying under the profit test (Listing Rule 1.2)

52. Evidence that the entity is a going concern or the successor of a going concern (Listing Rule 1.2.1)	N/A
53. Evidence that the entity has been in the same main business activity for the last 3 full financial years (Listing Rule 1.2.2)	N/A
54. Audited accounts for the last 3 full financial years, including the audit reports (Listing Rule 1.2.3(a))	N/A
55. If the entity's last financial year ended more than 6 months and 75 days before the date of this application, audited or reviewed accounts for the last half year (or longer period if available), including the audit report or review (Listing Rule 1.2.3(b))	N/A
56. A reviewed pro forma statement of financial position, including the review (Listing Rule 1.2.3(c)) <sup>31</sup>	N/A
57. Evidence that the entity's aggregated profit from continuing operations for the last 3 full financial years has been at least \$1 million (Listing Rule 1.2.4)	N/A
58. Evidence that the entity's profit from continuing operations in the past 12 months to a date no more than 2 months before the date of this application has exceeded \$500,000 (Listing Rule 1.2.5)	N/A
59. Is there a statement in the Offer Document that the entity's directors <sup>32</sup> have made enquiries and nothing has come to their attention to suggest that the entity is not continuing to earn profit from continuing operations up to the date of the Offer Document If so, where is it? If not, please attach such a statement signed by all of the entity's directors <sup>33</sup> (Listing Rule 1.2.6)	N/A

### Entities applying under the assets test (Listing Rule 1.3)

60. Evidence that the entity has:	Evidence of (a)
-----------------------------------	-----------------

<sup>31</sup> The review must be conducted by a registered company auditor (or if the entity is a foreign entity, an overseas equivalent of a registered company auditor) or independent accountant.

<sup>32</sup> If the entity applying for admission to the official list is a trust, the statement should be made by the directors of the responsible entity of the trust.

<sup>33</sup> If the entity applying for admission to the official list is a trust, the statement should be signed by all of the directors of the responsible entity of the trust.

Nº Item	Location/Confirmation
(a) if it is not an investment entity, net tangible assets of at least \$4 million (after deducting the costs of fund raising) or a market capitalisation of at least \$15 million; (b) if it is an investment entity other than pooled development fund, net tangible assets of at least \$15 million; or (c) if it is a pooled development fund, net tangible assets of at least \$2 million (Listing Rule 1.3.1 and 1.3.4)	Section 5 of the Prospectus – Statutory and Pro Forma Historical Statement of Financial Position Section 6 of the Prospectus – Investigating Accountant’s Report ‘Key Offer statistics’ section of the Prospectus (indicative market capitalisation at completion of the Offer)
61. Evidence that: (a) at least half of the entity’s total tangible assets (after raising any funds) is not cash or in a form readily convertible to cash; <sup>34</sup> or (b) there are commitments consistent with its stated objectives under Listing Rule 1.3.3(a) to spend at least half of the entity’s cash and assets in a form readily convertible to cash And if (b) above applies, where in the Offer Document is there an expenditure program setting out those commitments (Listing Rule 1.3.2)	Section 8.4 – Purpose of the offer and uses sources and uses of funds
62. Where in the Offer Document is there a statement setting out the objectives the entity is seeking to achieve from its admission and the offer (Listing Rule 1.3.3(a))?	Section 1.9 of the Prospectus – Proposed sources and uses of funds associated with the Offer Section 8.4 of the Prospectus – Purpose of the Offer and sources and uses of funds
63. Is there a statement in the Offer Document that the entity has enough working capital at the time of its admission to carry out those stated objectives? If so, where is it? If not, attach a statement by an independent expert confirming that the entity has enough working capital to carry out its stated objectives (Listing Rule 1.3.3(b))	Section 1.8 of the Prospectus – Will the Company be adequately funded after the Completion of the Offer? Section 5.9 of the Prospectus – Statutory and pro forma historical consolidated statement of financial position: details of cash and cash equivalents Section 8.4 of the Prospectus – Purpose of the Offer and sources and uses of funds
64. Evidence that the entity’s working capital (as shown in its reviewed pro forma statement of financial position under listing Rule 1.3.5(d)) is at least \$1.5 million (Listing Rule 1.3.3(c))	Section 5.9 of the Prospectus – Statutory and pro forma historical consolidated statement of financial position: details of cash and cash equivalents
65. Audited accounts for the last 2 full financial years, including the audit reports (Listing Rule 1.3.5(a))	<b>Tab 15 – FY24 and FY25</b>
66. If the entity’s last financial year ended more than 6 months and 75 days before the date of this application, audited or reviewed accounts for the last half year (or longer period if available), including the audit report or review (Listing Rule 1.3.5(b))	N/A
67. If the entity has in the 12 months before the date of this application acquired, or is proposing in connection with its application for admission to acquire, another entity or business that is significant in the context of the entity,	N/A

<sup>34</sup> In deciding if an entity’s total tangible assets are in a form readily convertible to cash, ASX would normally not treat inventories or receivables as readily convertible to cash.

Nº	Item	Location/Confirmation
	audited accounts for the last 2 full financial years for that other entity or business, including the audit reports (Listing Rule 1.3.5(c) first bullet point)	
68.	If the entity has in the 12 months before the date of this application acquired, or is proposing in connection with its application for admission to acquire, another entity or business that is significant in the context of the entity and the last full financial year for that other entity or business ended more than 6 months and 75 days before the date of this application, audited or reviewed accounts for the last half year (or longer period if available) from the end of the last full financial year for that other entity or business, including the audit report or review (Listing Rule 1.3.5(c) second bullet point)	N/A
69.	A reviewed pro forma statement of financial position, including the review (Listing Rule 1.3.5(d)) <sup>35</sup>	Section 5.9 of the Prospectus – Statutory and pro forma historical consolidated statement of financial position Section 6 of the Prospectus – Investigating Accountant's Report

### Entities with restricted securities

70.	A statement setting out a list of any person (either on their own or together with associates) who has held a relevant interest in at least 10% of the entity's voting securities at any time in the 12 months before the date of this application	N/A
71.	A completed ASX Restricted Securities Table <sup>36</sup>	N/A
72.	A list of all security holders sent a restriction notice (Appendix 9C) in relation to restricted securities and a sample of the restriction notice (Listing Rule 9.1(c)) <sup>37</sup>	N/A
73.	If the entity intends to use a third party to maintain its issuer sponsored sub-register, a written undertaking from that third party to comply with Listing Rule 9.1(e) (Listing Rule 9.1(f))	N/A
74.	Are any of the restricted securities in a class that is not intended to be quoted on ASX?	N/A
	If so, a sample of the share certificate for the restricted securities with the statement required under Listing Rule 9.1(g)(iii).	N/A
	Undertaking(s) from a bank or recognised trustee to hold the certificates for the restricted securities in escrow (Listing Rule 9.1(g)(iv))	N/A
	If the entity intends to use a third party to maintain its certificated sub-register, a written undertaking from that third party to comply with Listing Rule 9.1(g) (Listing Rule 9.1(h))	N/A

<sup>35</sup> The review must be conducted by a registered company auditor (or if the entity is a foreign entity, an overseas equivalent of a registered company auditor) or independent accountant.

<sup>36</sup> An electronic copy of the ASX Restricted Securities Table is available from the ASX Compliance Downloads page on ASX's website.

<sup>37</sup> ASX will advise which restricted securities are required to be escrowed via a restriction notice under Listing Rule 9.1 as part of the admission and quotation decision. If properly completed restriction notices have not been provided to all such securities advised by ASX, that will need to be rectified prior to admission occurring and quotation commencing.

**Entities (other than mining exploration entities and oil and gas exploration entities) with classified assets<sup>38</sup>**

75. Within the 2 years preceding the date of the entity's application for admission to the official list, has the entity acquired, or entered into an agreement to acquire, a classified asset from any person?

If so, where in the Offer Document does it disclose:

- (a) the date of the acquisition or agreement;
- (b) full details of the classified asset, including any title particulars;
- (c) the name of the vendor;
- (d) if the vendor was not the beneficial owner of the classified asset at the date of the acquisition or agreement, the name of the beneficial owner(s);
- (e) details of the relationship between the vendor (or, if the vendor was not the beneficial owner of the classified asset at the date of the acquisition or agreement, between the beneficial owner(s)) and the entity or any related party or promoter of, or adviser to, the entity; and
- (f) details of the purchase price paid or payable and all other consideration (whether legally enforceable or not) passing directly or indirectly to the vendor,

and, if the vendor acquired the classified asset from a third party within that 2 year period, the equivalent details to those set out above in relation to the arrangements between the vendor and the third party?

N/A

Is the vendor (or, if the vendor was not the beneficial owner of the classified asset at the date of the acquisition or agreement, are any of the beneficial owner(s)) a related party or promoter of the entity or an associate of a related party or promoter of the entity?

If so, please enter "Confirmed" in the column to the right to indicate that the consideration paid by the entity for the classified asset was solely restricted securities, save to the extent it involved the reimbursement of expenditure incurred by the vendor in developing the classified asset<sup>39</sup> or the entity was not required to apply the restrictions in Appendix 9B under Listing Rule 9.2 (Listing Rule 1.1 Condition 11)

N/A

If cash is being paid or proposed to be paid in connection with the acquisition of a classified asset from a related party or promoter, please provide supporting documentation to demonstrate that it was for the reimbursement of expenditure incurred by the vendor in developing the classified asset

N/A

Please also provide a copy of the agreement(s) relating to the acquisition entered into by the entity and any expert's report or valuation obtained by the entity in relation to the acquisition

N/A

**Mining entities**

76. A completed Appendix 1A Information Form and Checklist Annexure 1 (Mining Entities)<sup>40</sup>

N/A

<sup>38</sup> A "classified asset" is defined in Listing Rule 19.12 as:

- (a) an interest in a mining exploration area or oil and gas exploration area or similar tenement or interest;
- (b) an interest in intangible property that is substantially speculative or unproven, or has not been profitably exploited for at least three years, and which entitles the entity to develop, manufacture, market or distribute the property;
- (c) an interest in an asset which, in ASX's opinion, cannot readily be valued; or
- (d) an interest in an entity the substantial proportion of whose assets (held directly, or through a controlled entity) is property of the type referred to in paragraphs (a), (b) and (c) above.

<sup>39</sup> ASX may require evidence to support expenditure claims.

<sup>40</sup> An electronic copy of this Appendix is available from the ASX Compliance Downloads page on ASX's website.

Nº Item	Location/Confirmation
<b>Oil and gas entities</b>	
77. A completed Appendix 1A Information Form and Checklist Annexure 2 (Oil and Gas Entities) <sup>41</sup>	N/A
<b>Entities incorporated or established outside of Australia</b>	
78. A completed Appendix 1A Information Form and Checklist Annexure 3 (Foreign Entities) <sup>42</sup>	Tab 16 – Annexure 3
<b>Externally managed entities</b>	
79. A completed Appendix 1A Information Form and Checklist Annexure 4 (Externally Managed Entities) <sup>43</sup>	N/A
<b>Stapled entities</b>	
80. A completed Appendix 1A Information Form and Checklist Annexure 5 (Stapled Entities) <sup>44</sup>	N/A

### Further documents to be provided before admission to the official list

In addition to the information and documents mentioned above, entities will be required to provide the following before their admission to the official list and the quotation of their securities commences:

- A statement setting out the names of the 20 largest holders in each class of securities to be quoted, and the number and percentage of each class of securities held by those holders;
- A distribution schedule of each class of equity securities to be quoted, setting out the number of holders in the following categories and the total percentage of the securities in that class held by the recipients in each category:
  - 1 - 1,000
  - 1,001 - 5,000
  - 5,001 - 10,000
  - 10,001 - 100,000
  - 100,001 and over
- The number of holders of a parcel of securities (excluding restricted securities or securities subject to voluntary escrow) with a value of more than \$2,000, based on the issue/sale price;
- Any outstanding restriction notices (Appendix 9C) and related undertakings;
- Any other information that ASX may require under Listing Rule 1.17;<sup>45</sup> and
- A statement disclosing the nature and effect of any waiver(s) granted and the entity's reasons for seeking them.

<sup>41</sup> An electronic copy of this Appendix is available from the ASX Compliance Downloads page on ASX's website.

<sup>42</sup> An electronic copy of this Appendix is available from the ASX Compliance Downloads page on ASX's website.

<sup>43</sup> An electronic copy of this Appendix is available from the ASX Compliance Downloads page on ASX's website.

<sup>44</sup> An electronic copy of this Appendix is available from the ASX Compliance Downloads page on ASX's website.

<sup>45</sup> Among other things, this may include evidence to verify that an entity has met Listing Rule 1 Condition 8 and achieved minimum spread without using artificial means (see Guidance Note 1 section 3.9).

# Information Form and Checklist

## Annexure 3 (Foreign Entities)

Name of entity

ABN/ACN/ARBN/ARSN

**Saluda Medical, Inc.**

**691 140 360**

**This Annexure forms part of the Information Form and Checklist supplied by the entity named above to support its application for admission to the official list of ASX Limited (ASX) as an ASX Listing.**

Nº Item

Location

1. Evidence that the entity is registered as a foreign company in Australia (Listing Rule 1.1 Condition 4)

Tab 1.2 – Certificate of Registration of a Foreign Company

2. Where in the Offer Document does it state the entity's place of incorporation, registration or establishment (Guidance Note 4 section 3.2)?

Section 12.1 of the Prospectus – Incorporation and Registration as a foreign company

3. Where in the Offer Document does it include a statement to the effect that: "As [*name of entity*] is not established in Australia, its general corporate activities (apart from any offering of securities in Australia) are not regulated by the Corporations Act 2001 of the Commonwealth of Australia or by the Australian Securities and Investments Commission but instead are regulated by [*insert name of governing legislation*] and [*insert name of corporate regulator administering that legislation*]." (Guidance Note 4 section 3.2)?

Prospectus – Important Information

4. Where in the Offer Document does it include a concise summary of the rights and obligations of security holders under the law of its home jurisdiction covering:

- what types of transactions require security holder approval;
- whether security holders have a right to request or requisition a meeting of security holders;
- whether security holders have a right to appoint proxies to attend and vote at meetings on their behalf;
- how changes in the rights attaching to securities are regulated;
- what rights do security holders have to seek relief for oppressive conduct;
- what rights do security holders have to bring or intervene in legal proceedings on behalf of the entity; and
- whether there is any equivalent to the "two strikes" rule in relation to remuneration reports in Part 2G.2 Division 9 of the Corporations Act (Guidance Note 4 section 3.2)?<sup>1</sup>

Section 12.9 of the Prospectus – Certificate of Incorporation, Bylaws and rights attaching to shares

Section 12.10 of the Prospectus – Differences between Australian and U.S. Law

5. Where in the Offer Document does it include a concise summary of how the disclosure of substantial holdings and takeovers are regulated under the law of its home jurisdiction (Guidance Note 4 section 3.2)?<sup>2</sup>

Section 12.9 of the Prospectus – Certificate of Incorporation, Bylaws and rights attaching to shares (takeovers)

6. Where in the Offer Document does it include a summary of any taxes or duties payable in its place of incorporation, registration or establishment by an investor in relation to the acquisition, holding or disposal of securities in the entity or, if there are no such taxes or duties, a statement to that effect (Guidance Note 4 section 3.2)?

Section 11.2 of the Prospectus – U.S. Taxation

<sup>1</sup> The concise summary is not intended to be a legal treatise on the laws of the entity's home jurisdiction or a detailed comparative analysis of those laws with the laws of Australia. For those matters where the entity's home jurisdiction has broadly comparable laws to Australia, a statement to that effect will generally suffice.

<sup>2</sup> See note 1 above.

Nº	Item	Location
7.	Where in the Offer Document does it disclose what accounting standards have been used to prepare the pro forma statement of financial position in the Offer Document (Listing Rules 1.2.3(c) and 1.3.5(d))?  Note: Those accounting standards must be Australian Accounting Standards, International Financial Reporting Standards (IFRS) as adopted by the EU, or the accounting standards and generally accepted accounting principles applied in Bermuda, Canada, Cayman Islands, Hong Kong, New Zealand, Singapore, South Africa or USA, or otherwise ASX must specifically agree to the use of those accounting standards (Listing Rule 19.11A(b) and Guidance Note 4 section 3.6).	Section 5.2 of the Prospectus – Basis of presentation of the Historical Consolidated Financial Information  Section 13 of the Prospectus – Summary of the Company's Significant Accounting Policies
8.	Where in the Offer Document does it disclose what auditing standards were applied to the review of the pro forma statement of financial position in the Offer Document (Listing Rules 1.2.3(c) and 1.3.5(d))?  Note: those auditing standards must be Australian Auditing Standards, International Standards on Auditing or US Auditing Standards, or otherwise ASX must specifically agree to the use of those auditing standards (Listing Rule 19.11A(c) and Guidance Note 4 section 3.6).	Section 5.2.2 of the Prospectus – Basis of preparation of the Historical Consolidated Financial Information
9.	Where in the Offer Document does it disclose what accounting standards the entity will apply to the preparation of its financial statements after it is listed?	Section 5.1.2 of the Prospectus – Reconciliation between USGAAP and IFRS  Section 13 of the Prospectus – Summary of the Company's Significant Accounting Policies
10.	If those accounting standards are not Australian Accounting Standards, International Financial Reporting Standards (IFRS) as adopted by the EU, or the accounting standards and generally accepted accounting principles applied in Bermuda, Canada, Cayman Islands, Hong Kong, New Zealand, Singapore, South Africa or USA, where in the offer document does it disclose that ASX has agreed to the use of those accounting standards (Listing Rule 19.11A(b) and Guidance Note 4 section 3.6)?	N/A
11.	Where in the Offer Document does it disclose what auditing standards the entity's auditor will apply to the entity's financial statements after it is listed?	Section 5.12 of the Prospectus – Reconciliation between USGAAP and IFRS
12.	If those auditing standards are not Australian Auditing Standards, International Standards on Auditing or US Auditing Standards, where in the Offer Document does it disclose that ASX has agreed to the use of those auditing standards (Listing Rule 19.11A(c) and Guidance Note 4 section 3.6)?	N/A
13.	If any class of securities which you are seeking to have quoted on ASX will not have CDIs issued over them, please obtain and provide an International Securities Identification Number (ISIN) for that class (ASX is unable to create the new ISIN for non-Australian issuers).	N/A